新发Ⅳ期乳腺癌患者手术价值探讨

doi:10.19401/j.cnki.1007-3639.2023.05.002

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (5): 431-436.doi: 10.19401/j.cnki.1007-3639.2023.05.002

新发Ⅳ期乳腺癌患者手术价值探讨

陈璐艳(), 王丽雪, 傅佩芬()

浙江大学医学院附属第一医院乳腺外科，浙江杭州 310009

收稿日期:2023-01-31 修回日期:2023-05-04 出版日期:2023-05-30 发布日期:2023-06-16
作者简介:陈璐艳（ORCID: 0000-0002-3999-9953），硕士，主治医师。
傅佩芬，主任医师，外科学博士，硕士研究生导师，浙江大学医学院附属第一医院乳腺外科主任。从事乳腺疾病诊治工作30年，致力于乳腺癌耐药机制及细胞免疫治疗研究，主持国家自然科学基金、浙江省重点研发计划项目等国家及省部级课题7项。目前在研项目国家自然科学基金面上项目及浙江省重点研发项目各1项，总经费达305万元。研发设计的乳腺癌腋窝淋巴结清扫压力胸衣，获批国家实用新型发明专利。以第一作者或通信作者在SCI收录期刊上发表乳腺疾病相关论文30余篇。先后担任中国临床肿瘤学会（Chinese Society of Clinical Oncology，CSCO）乳腺癌专家委员会常委、中国医药教育协会乳腺疾病专业委员会常委、中国医疗保健国际交流促进会乳腺疾病分会常委、中国抗癌协会乳腺癌专业委员会委员、中国医师协会外科医师分会乳腺外科医师委员会委员、中华医学会外科学分会乳腺外科学组委员、浙江省数理医学学会乳腺临床试验专业委员会主任委员等。参与《中国临床肿瘤学会（CSCO）乳腺癌诊疗指南》《中国早期乳腺癌前哨淋巴结活检手术临床实践指南（2022版）》《乳腺肿瘤整形与乳房重建专家共识》《中国浸润性乳腺癌诊治临床实践指南（2022版）》《中华医学会乳腺外科临床实践指南》《乳腺癌腔镜治疗专家共识与操作指导意见（2019版）》《乳腺及引流区域淋巴结介入超声若干临床常见问题中国专家共识（2021版）》《中国可视化经皮穿刺乳腺组织定位导丝与定位标记夹临床实践指南（2022版）》《乳腺癌靶向人表皮生长因子受体2酪氨酸激酶抑制剂不良反应管理共识》《妊娠相关性乳腺癌临床诊治专家共识（2020版）》等多部全国乳腺疾病诊疗指南与共识的修订，2021年获聘CSCO AI乳腺癌规范化诊疗项目首席专家。
基金资助:
国家自然科学基金面上项目(82172770)

The value of surgery in the patients with de novo stage Ⅳ breast cancer

CHEN Luyan(), WANG Lixue, FU Peifen()

Department of Breast Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China

Received:2023-01-31 Revised:2023-05-04 Published:2023-05-30 Online:2023-06-16

摘要/Abstract

摘要：

乳腺癌是全世界常见的恶性肿瘤之一，其中约6%的患者为新发Ⅳ期乳腺癌，是不可治愈的。传统意义上外科手术的作用仅限于缓解患者症状，改善生活质量，降低肿瘤负荷。随着全身治疗手段的进步，通过多学科团队制订综合治疗方案，仅有寡转移灶的Ⅳ期乳腺癌患者往往能获得长期生存，而原发灶及转移灶的R0切除可以延长无进展生存期（progression-free survival，PFS），可能会带来生存获益，因此是否需要行乳腺癌原发灶及转移灶的手术治疗成为临床热点，并存在较大争议。本文对新发Ⅳ期乳腺癌患者的手术价值进行深入探讨。

关键词: Ⅳ期乳腺癌, 手术, 多学科团队, 寡转移灶, 生存获益

Abstract:

Breast cancer is one of the common malignant tumors in the world. About 6% of the patients are de novo stage Ⅳ breast cancer, which is incurable. Traditionally, the role of surgery has been confined to relieving symptoms, improving quality of life and reducing tumor load. Nowadays, a multidisciplinary team is a prerequisite for optimal management, and patients with oligometastatic lesion always live for a long time. R0 resection of the primary and metastatic foci can extend the time of progression-free survival (PFS), which may bring survival benefits. Therefore, whether to perform surgery has become a hot clinical issue. This article deeply discussed extensively the surgical value in de novo stage Ⅳ breast cancer patients.

Key words: Stage Ⅳ breast cancer, Surgery, Multidisciplinary team, Oligometastatic lesion, Survival benefit

中图分类号:

R737.9

陈璐艳, 王丽雪, 傅佩芬. 新发Ⅳ期乳腺癌患者手术价值探讨[J]. 中国癌症杂志, 2023, 33(5): 431-436.

CHEN Luyan, WANG Lixue, FU Peifen. The value of surgery in the patients with de novo stage Ⅳ breast cancer[J]. China Oncology, 2023, 33(5): 431-436.

参考文献 38

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.v71.3
[2]	GIAQUINTO A N, SUNG H, MILLER K D, et al. Breast cancer statistics, 2022[J]. CA A Cancer J Clin, 2022, 72(6): 524-541. doi: 10.3322/caac.v72.6
[3]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2015[J]. CA A Cancer J Clin, 2015, 65(1): 5-29. doi: 10.3322/caac.21254
[4]	ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Center, 2022, 2(1): 1-9. doi: 10.1016/j.jncc.2022.02.002
[5]	ARCIERO C, LIU Y, GILLESPIE T, et al. Surgery and survival in patients with stage Ⅳ breast cancer[J]. Breast J, 2019, 25(4): 644-653. doi: 10.1111/tbj.2019.25.issue-4
[6]	ZHENG A, GUO B L, ZHANG J G, et al. Clinical information and management status of de novo stage Ⅳ breast cancer patients: a Chinese multicenter investigation (CSBrS-002)[J]. Chin Med J (Engl), 2021, 134(13): 1569-1575.
[7]	MALINOWSKI C, LEI X D, ZHAO H, et al. Association of Medicaid expansion with mortality disparity by race and ethnicity among patients with de novo stage Ⅳ breast cancer[J]. JAMA Oncol, 2022, 8(6): 863-870. doi: 10.1001/jamaoncol.2022.0159
[8]	MALMGREN J A, MAYER M, ATWOOD M K, et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010[J]. Breast Cancer Res Treat, 2018, 167(2): 579-590. doi: 10.1007/s10549-017-4529-5
[9]	GRADISHAR W J, MORAN M S, ABRAHAM J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722. doi: 10.6004/jnccn.2022.0030
[10]	中华医学会外科学分会. 乳腺外科临床实践指南(2022版)[M]. 人民卫生出版社, 2022.
	Surgery Branch of Chinese Medical Association. Practice guidelines of Chinese society of breast surgery (2022)[M]. People’s Medical Publishing House, 2022.
[11]	GENNARI A, ANDRÉ F, BARRIOS C H, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer[J]. Ann Oncol, 2021, 32(12): 1475-1495. doi: 10.1016/j.annonc.2021.09.019 pmid: 34678411
[12]	SI Y R, YUAN P, HU N L, et al. Primary tumor surgery for patients with de novo stage Ⅳ breast cancer can decrease local symptoms and improve quality of life[J]. Ann Surg Oncol, 2020, 27(4): 1025-1033. doi: 10.1245/s10434-019-08092-2
[13]	YU Y F, HONG H M, WANG Y, et al. Clinical evidence for locoregional surgery of the primary tumor in patients with de novo stage Ⅳ breast cancer[J]. Ann Surg Oncol, 2021, 28(9): 5059-5070. doi: 10.1245/s10434-021-09650-3
[14]	KHAN S A, ZHAO F M, GOLDSTEIN L J, et al. Early local therapy for the primary site in de novo stage Ⅳ breast cancer: results of a randomized clinical trial (EA2108)[J]. J Clin Oncol, 2022, 40(9): 978-987. doi: 10.1200/JCO.21.02006
[15]	KHAN S A, STEWART A K, MORROW M. Does aggressive local therapy improve survival in metastatic breast cancer?[J]. Surgery, 2002, 132(4): 620-6;discussion626.
[16]	BABIERA G V, RAO R, FENG L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage Ⅳ disease and an intact primary tumor[J]. Ann Surg Oncol, 2006, 13(6): 776-782. doi: 10.1245/ASO.2006.03.033
[17]	RAPITI E, VERKOOIJEN H M, VLASTOS G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis[J]. J Clin Oncol, 2006, 24(18): 2743-2749. doi: 10.1200/JCO.2005.04.2226 pmid: 16702580
[18]	BAFFORD A C, BURSTEIN H J, BARKLEY C R, et al. Breast surgery in stage Ⅳ breast cancer: impact of staging and patient selection on overall survival[J]. Breast Cancer Res Treat, 2009, 115(1): 7-12. doi: 10.1007/s10549-008-0101-7
[19]	LANE W O, THOMAS S M, BLITZBLAU R C, et al. Surgical resection of the primary tumor in women with de novo stage Ⅳ breast cancer: contemporary practice patterns and survival analysis[J]. Ann Surg, 2019, 269(3): 537-544. doi: 10.1097/SLA.0000000000002621
[20]	SORAN A, OZMEN V, OZBAS S, et al. Primary surgery with systemic therapy in patients with de novo stage Ⅳ breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial[J]. J Am Coll Surg, 2021, 233(6): 742-751.e5. doi: 10.1016/j.jamcollsurg.2021.08.686
[21]	BADWE R, PARMAR V, HAWALDAR R, et al. Abstract S2-02: surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial[J]. Cancer Res, 2013, 73(24_Supplement): S2-2.
[22]	BADWE R, HAWALDAR R, NAIR N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial[J]. Lancet Oncol, 2015, 16(13): 1380-1388. doi: 10.1016/S1470-2045(15)00135-7 pmid: 26363985
[23]	KING T A, LYMAN J P, GONEN M, et al. Prognostic impact of 21-gene recurrence score in patients with stage Ⅳ breast cancer: TBCRC 013[J]. J Clin Oncol, 2016, 34(20): 2359-2365. doi: 10.1200/JCO.2015.63.1960
[24]	RAO R, FENG L, KUERER H M, et al. Timing of surgical intervention for the intact primary in stage Ⅳ breast cancer patients[J]. Ann Surg Oncol, 2008, 15(6): 1696-1702. doi: 10.1245/s10434-008-9830-4
[25]	ZHU S Y. Exploring the value of additional primary tumour excision combined with systemic therapy administered in different sequences for patients with de novo metastatic breast cancer[J]. Breast J, 2022, 2022: 5049445.
[26]	KOMMALAPATI A, TELLA S H, GOYAL G, et al. A prognostic scoring model for survival after locoregional therapy in de novo stage Ⅳ breast cancer[J]. Breast Cancer Res Treat, 2018, 170(3): 677-685. doi: 10.1007/s10549-018-4802-2
[27]	GERA R, CHEHADE H E L H, WAZIR U, et al. Locoregional therapy of the primary tumour in de novo stage Ⅳ breast cancer in 216 066 patients: a meta-analysis[J]. Sci Rep, 2020, 10(1): 2952. doi: 10.1038/s41598-020-59908-1
[28]	POCKAJ B A, WASIF N, DUECK A C, et al. Metastasectomy and surgical resection of the primary tumor in patients with stage Ⅳ breast cancer: time for a second look?[J]. Ann Surg Oncol, 2010, 17(9): 2419-2426. doi: 10.1245/s10434-010-1016-1
[29]	BILANI N, ELSON L, LIANG H, et al. Effect of surgery at primary and metastatic sites in patients with stage Ⅳ breast cancer[J]. Clin Breast Cancer, 2021, 21(3): 170-180. doi: 10.1016/j.clbc.2020.08.008
[30]	BILANI N, YAGHI M, SINGH JABBAL I, et al. Survival benefit of a combined surgical approach in patients with metastatic breast cancer[J]. J Surg Oncol, 2021, 124(8): 1235-1241. doi: 10.1002/jso.v124.8
[31]	HELLMAN S, WEICHSELBAUM R R. Oligometastases[J]. J Clin Oncol, 1995, 13(1): 8-10. doi: 10.1200/JCO.1995.13.1.8 pmid: 7799047
[32]	CARDOSO F, PALUCH-SHIMON S, SENKUS E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)[J]. Ann Oncol, 2020, 31(12): 1623-1649. doi: 10.1016/j.annonc.2020.09.010
[33]	LACAZE J L, AZIZA R, CHIRA C, et al. Diagnosis, biology and epidemiology of oligometastatic breast cancer[J]. Breast, 2021, 59: 144-156. doi: 10.1016/j.breast.2021.06.010
[34]	BILANI N, YAGHI M, MAIN O, et al. Metastasectomy versus radiation of secondary sites in stage Ⅳ breast cancer: analysis from a national cancer registry[J]. Breast, 2021, 60: 185-191. doi: 10.1016/j.breast.2021.10.005
[35]	IMOTO S, WANG K, BI X W, et al. Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)[J]. Breast Cancer, 2023, 30(3): 412-423. doi: 10.1007/s12282-023-01436-7 pmid: 36689066
[36]	SADOT E, LEE S Y, SOFOCLEOUS C T, et al. Hepatic resection or ablation for isolated breast cancer liver metastasis: a case-control study with comparison to medically treated patients[J]. Ann Surg, 2016, 264(1): 147-154. doi: 10.1097/SLA.0000000000001371 pmid: 26445472
[37]	CHMURA S J, WINTER K A, WOODWARD W A, et al. NRG-BR002: a phase ⅡR/Ⅲ trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)[J]. J Clin Oncol, 2022, 40: 1007. doi: 10.1200/JCO.2022.40.16_suppl.1007
[38]	ZHENG C, YU Z G, CHINESE SOCIETY OF BREAST SURGERY. Clinical practice guidelines for pre-operative evaluation of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021[J]. Chin Med J (Engl), 2021, 134(18): 2147-2149.

新发Ⅳ期乳腺癌患者手术价值探讨

The value of surgery in the patients with de novo stage Ⅳ breast cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏春霞, 周彩存. 2022年度肺癌领域重要临床研究进展[J]. 中国癌症杂志, 2023, 33(3): 218-227.
[2]	李峰, 唐学虎, 曾棒, 陈明华. 行电视胸腔镜辅助手术的老年食管癌患者心血管不良反应发生风险的影响因素及列线图模型构建[J]. 中国癌症杂志, 2023, 33(3): 282-287.
[3]	刘文生, 吉顺荣, 卓奇峰, 高鹤丽, 史逸华, 许文彦, 刘梦奇, 李征, 虞先濬, 陈洁, 徐晓武. 机器人与腹腔镜微创手术治疗分化良好的胰腺神经内分泌瘤的临床研究[J]. 中国癌症杂志, 2022, 32(9): 786-793.
[4]	马晓, 相加庆, 马龙飞. 局部进展期食管癌新辅助化疗导致的食管气管瘘的手术治疗：1例报道[J]. 中国癌症杂志, 2022, 32(6): 542-544.
[5]	周长帅, 杨越超, 崔欢欢, 陈磊, 陈鑫, 郝斌, 童彤, 曹依群. 36例小脑转移瘤外科治疗及预后因素分析[J]. 中国癌症杂志, 2022, 32(4): 357-362.
[6]	徐宇, 陈勇, 杨吉龙, 朱冠男. Ⅲ期黑色素瘤围手术期治疗的现状与展望[J]. 中国癌症杂志, 2022, 32(12): 1133-1146.
[7]	周明梁, 宋章法, 李振军. 腹部无辅助切口的达芬奇机器人手术切除直肠间质瘤1例[J]. 中国癌症杂志, 2022, 32(1): 75-79.
[8]	袁　浩, 蒋晓飞, 游庆华, 朱红波, 叶慧英, 伍　雯, 钱丰源, 钟　明, 李永平 . 甲状旁腺细针穿刺Diff-Quik染色在甲状腺癌手术中的临床应用[J]. 中国癌症杂志, 2021, 31(4): 302-307.
[9]	曾　峰, 李　丹, 邵鑫鑫, 张能英, 陈星翰, 程晓明 . 基于SEER数据库构建1~2枚淋巴结阳性且乳房全切的老年早期乳腺癌患者不同腋窝手术方式的生存预测模型[J]. 中国癌症杂志, 2021, 31(4): 323-329.
[10]	杨柳松, 祝迎锋, 唐剑敏 . 上皮样胶质母细胞瘤10例报告并文献复习[J]. 中国癌症杂志, 2021, 31(2): 114-120.
[11]	李　飞, 宋　媛, 李　芳, 朱希燕, 何　明 . 食管胃交界部腺癌SiewertⅠ型和Ⅱ型胸外科手术治疗效果及预后研究[J]. 中国癌症杂志, 2021, 31(2): 143-150.
[12]	龙克艰, 杨　超, 吴　强, 查　炜. 甲状腺术中喉不返神经的解剖特点及神经监测的使用[J]. 中国癌症杂志, 2021, 31(10): 927-931.
[13]	王　迪, 陈　锋, 金艳玲, 孙志刚, 白珊珊, 崔晓楠, 张　斌. 原发性睾丸旁平滑肌肉瘤1例报告[J]. 中国癌症杂志, 2020, 30(9): 718-720.
[14]	中国抗癌协会泌尿男生殖系肿瘤专业委员会, 中国临床肿瘤学会前列腺癌专家委员会, 中国肿瘤医院泌尿肿瘤协作组, 上海市泌尿肿瘤研究所. 泌尿男生殖系统肿瘤多学科团队诊治组织与实施规范中国专家共识（2020年版）[J]. 中国癌症杂志, 2020, 30(4): 313-320.
[15]	石志强 , 邱鹏飞 , 刘雁冰 , 赵　桐 , 孙　晓 , 陈　鹏 , 王春建 , 张朝蓬 , 丛斌斌 , 王永胜 . HER2阳性和三阴性乳腺癌新辅助化疗后选择性避免腋窝手术分期的研究[J]. 中国癌症杂志, 2020, 30(3): 186-191.